Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics

By Sehrt Daniel   Meineke Ingolf   Tzvetkov Mladen   Güültepe Senol   Brockmööller Jüürgen  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 783-795

Future Medicine

Access to resources Recommend Favorite

Translation of CYP2D6 Human Genetic Variation into Medical Practice: Lessons Learned and the Way Forward

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 8, Iss. 4, 2010-12 ,pp. : 306-319

Bentham Science Publishers

Access to resources Recommend Favorite

Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype

By Kaila Nitin   Straka Robert   Brundage Richard  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 34, Iss. 2, 2007-04 ,pp. : 141-156

Springer Publishing Company

Access to resources Recommend Favorite

Effects of Polymorphism of the β₁ Adrenoreceptor and CYP2D6 on the Therapeutic Effects of Metoprolol

By Yuan H   Huang Z   Yang G   Lv H   Sang H   Yao Y  

The Journal of International Medical Research, Vol. 36, Iss. 6, 2008-11 ,pp. : 1354-1362

Field House Publishing

Access to resources Recommend Favorite

The effect of mirabegron, a potent and selective β₃-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol

By Krauwinkel Walter   Dickinson James   Schaddelee Marloes   Meijer John   Tretter Reiner   Wetering Jeroen   Strabach Gregory   Gelderen Marcel  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 43-52

Springer Publishing Company

Access to resources Recommend Favorite